Capvizr
News · All summaries
Healthcare & Life Sciences
EG427
Series C$37.7 million
RoundSeries C
Amount$37.7 million
HQParis, France
DateJuly 7, 2026
THE DEAL, AT A GLANCE

EG427

From the announcement
Who is involvedBacked by this authorFrom the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
What happenedEG427 raised $37.7M Series C, announced 2026-07-07From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Why it mattersEG427's $37.7M Series C is a below-median Healthcare & Life Sciences financing in an active funding market, signaling continued capital availability for HSV gene therapy…From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

EG427 · Financing Record

Explore source-linked visual explanations for EG427. Unsupported claims are withheld while source review continues.

Record 7702 · Recorded date: 2026-07-07

Explore company records →
Free weekday briefing

Know which funding rounds matter before the first call.

Source-linked rounds, lead investors, and the signal behind the capital. One five-minute read.

Free · Unsubscribe anytime